Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. It has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., Merck &Co., Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Mercer Island, Washington.
Frequently asked questions
What sector does Kineta, Inc. (KANT) operate in?
Kineta, Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is Kineta, Inc. (KANT) current stock price?
As of the latest data, Kineta, Inc. stock price is $0.34, with a previous close of $0.34.
What is Kineta, Inc. (KANT) current market capitalization?
Kineta, Inc. market cap is approximately 4.12 million.
What is Kineta, Inc. (KANT) Earnings Per Share (EPS)?
The trailing EPS is -$1.64.
Does Kineta, Inc. (KANT) pay dividends?
No. Kineta, Inc. does not pay a dividend.
What is Kineta, Inc. (KANT) beta (volatility) score?
Kineta, Inc. has a beta of -3.663, indicating lower volatility than the overall market.
